Abstract: The invention relates to nutritional compositions with Bifidobacterium breve and non-digestible oligosaccharides for use infants or toddlers for use in improving cognitive or behavioral performance or neuroinflammation.

Abstract: The invention relates to nutritional compositions with Bifidobacterium breve and non-digestible oligosaccharides selected from the group consisting of fructo-oligosaccharides, galacto-oligosaccharides, gluco-oligosaccharides, arabino-oligosaccharides, mannan-oligosaccharides, xylo-oligosaccharides, fuco-oligosaccharides, arabinogalacto-oligosaccharides, glucomanno-oligosaccharides, galactomanno-oligosaccharides, sialic acid comprising oligosaccharides and uronic acid oligosaccharides for use in improving cognitive or behavioral performance, cognitive or behavioral development, social interaction and/or neuroinflammation in infants or toddlers. Also claimed is the use of a nutritional compositions including Bifidobacterium breve, at least one non digestible oligosaccharide, glutamine in the form of free amino acids and/or glutamine containing dipeptide and/or glutaime containing tripeptide and LC-PUFA in the form or arachidonic acid and/or docosahexaenoic acid.

Abstract: The invention relates to the use of glutamine, preferably in the form of free amino acids, dipeptides and/or tripeptides, in the manufacture of a nutritional composition for improving exploratory behavior, memory performance, particularly spatial memory performance, and/or social interaction in an infant or toddler and/or treating or preventing impaired or decreased exploratory behavior, memory performance, particularly spatial memory performance, and/or social interaction in an infant or toddler.

Abstract: The invention relates to nutritional compositions with Bifidobacterium breve and non-digestible oligosaccharides selected from the group consisting of fructo-oligosaccharides, galacto-oligosaccharides, gluco-oligosaccharides, arabino-oligosaccharides, mannan-oligosaccharides, xylo-oligosaccharides, fuco-oligosaccharides, arabinogalacto-oligosaccharides, glucomanno-oligosaccharides, galactomanno-oligosaccharides, sialic acid comprising oligosaccharides and uronic acid oligosaccharides for use in improving cognitive or behavioral performance, cognitive or behavioral development, social interaction and/or neuroinflammation in infants or toddlers. Also claimed is the use of a nutritional compositions including Bifidobacterium breve, at least one non digestible oligosaccharide, glutamine in the form of free amino acids and/or glutamine containing dipeptide and/or glutaime containing tripeptide and LC-PUFA in the form or arachidonic acid and/or docosahexaenoic acid.

Abstract: The invention relates to a compound inhibiting the binding of the free light chain of immunoglobulin (Ig LC) to mast cells. It has been found that Ig LC is the agent responsible for the sensitization of mast cells. The compounds according to the invention can thus be used for the preparation of a drug for the treatment of a disease whose symptom is an elevated Ig LC concentration in serum or spinal fluid. The invention also relates to a method of screening a series of compounds on their ability to reduce the sensitization of mast cells.

Abstract: The invention relates to a compound inhibiting the binding of the free light chain of immunoglobin (Ig LC) to mast cells. It has been found that Ig LC is the agent responsible for the sensitization of mast cells. The compounds according to the invention can thus be used for the preparation of a drug for the treatment of a disease whose symptom is an elevated Ig LC concentration in serum or spinal fluid. The invention also relates to a method of screening a series of compounds on their ability to reduce the sensitization of mast cells.